Orphazyme A/S (ORPH) Stock Analysis
DELISTED
What happened to Orphazyme A/S (ORPH) stock?
Orphazyme A/S (ORPH) no longer trades on public markets. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
P/E 20.13 means the share price is 20.13 times one year of earnings per share.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Orphazyme A/S (ORPH). Orphazyme A/S is a biopharmaceutical company focused on developing therapies for neurodegenerative orphan diseases. Their lead candidate, Arimoclomol, is in clinical development for Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease.
Last analyzed: Mar 18, 2026Dated analysis: the newest financial statements on file are 28 months old (Jun 1, 2024), so the figures and score below describe that period, not today.
Orphazyme A/S (ORPH) Healthcare & Pipeline Overview
Orphazyme A/S ADR Information Sponsored
Orphazyme A/S (ORPH) trades in the U.S. as an American Depositary Receipt (ADR).
- ADR Level: 2
- ADR Ratio: 1:1
More about this archive record
Can I still buy ORPH shares?
No. ORPH stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for ORPH elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before ORPH stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Orphazyme A/S. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.